This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Thirty-Day Safety and Efficacy Data Presented for Medtronic's Valiant Navion TEVAR System
At the Charing Cross Symposium, held April 15 to 18 in London, UK, Professor Fabio Verzini presented the 30-day data from Medtronic's Valiant Navion investigational device exemption study of 100 patients with thoracic aortic aneurysm and penetrating atherosclerotic ulcer. This study showed low rates of perioperative mortality at 2.0% and secondary procedures at 2.0%. The rate of type Ia endoleaks was 1.1% at imaging follow-up after one month.